NATICK, Mass., European regulators have approved an expanded indication for the Boston Scientific Corporation WATCHMAN ® Left Atrial Appendage (LAA) Closure Device. The new indication offers patients ...

Data also demonstrates that the stroke risk reduction device is as effective as oral anticoagulants for patients with atrial fibrillation following a cardiac ablation The trial met the primary safety ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Rates of patency and device-related thrombus were ...

The WATCHMAN(TM) Left Atrial Appendage Closure Device from Boston Scientific is an implant used to block the left atrial appendage of the heart, a common area for blood clot formations in patients ...

Please provide your email address to receive an email when new articles are posted on . OPTION is a head-to-head trial of left atrial appendage closure with Watchman FLX vs. anticoagulation after ...

MARLBOROUGH, Mass., May 8, 2020 /PRNewswire/ -- Today, Boston Scientific (NYSE: BSX) announced positive 12-month results from the PINNACLE FLX clinical trial assessing the safety and efficacy of the ...

W.L. Gore & Associates announced today that it agreed to acquire left atrial appendage occlusion (LAAO) device maker ...

Trial to study next-generation device as treatment alternative to NOACs for broader population of patients with non-valvular atrial fibrillation MARLBOROUGH, Mass., Oct. 29, 2020 /PRNewswire/ -- ...

New stroke risk reduction technology designed to advance procedural performance and safety, treat wider range of patients with non-valvular atrial fibrillation MARLBOROUGH, Mass., July 21, 2020 ...

Abbott's Amplatzer Amulet provided superior left atrial appendage (LAA) closure over the old-guard Watchman (Boston Scientific) device but failed to significantly cut stroke or bleeding rates in ...